Showing 1701-1710 of 5643 results for "".
- Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-positive-topline-results-for-its-seecase-phase-2-trial-of-nov03-for-the-treatment-of-patients-with-dry-eye-disease/2479732/Novaliq announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the first drug developed to treat evaporative DE
- Switzerland Eye Research Institute Publishes Breakthrough Case Report Using Light Exposure and Nutraceuticals for Treating Retinal Degenerationhttps://modernod.com/news/switzerland-eye-research-institute-publishes-breakthrough-case-report-using-light-exposure-and-nutraceuticals-for-treating-retinal-degeneration/2480653/Roberto Pinelli, MD, CEO of the Switzerland Eye Research Institute, announced the publication of a breakthrough paper in Archives Italiennes de Biologie. The report can be found here:
- LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patientshttps://modernod.com/news/lumithera-provides-update-on-fda-review-of-valeda-treatment-for-dry-amd-patients/2482040/LumiThera announced an update on the regulatory status of the Valeda Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as a Class II device has been submitted for review. Under the De Novo request process, the V
- Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Reporthttps://modernod.com/news/nordic-pharmas-lacrifill-canalicular-gel-highlighted-in-landmark-dews-iii-report/2482927/Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and O
- EssilorLuxottica Acquires Espansione Group, Provider of Noninvasive Ophthalmic Medical Deviceshttps://modernod.com/news/essilorluxottica-acquires-espansione-group-provider-of-noninvasive-ophthalmic-medical-devices/2482581/Optical giant EssilorLuxottica announced it is acquiring Italy-based Espansione Group, a provider of noninvasive medical devices for the diagnosis and treatment of dry eye, ocular surface and retinal diseases. Financial terms of the deal were not disclosed. Esp
- Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Betahttps://modernod.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/Amydis announced it has launched a phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients. "Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tes
- Novartis to Discontinue Development of GA Gene Therapyhttps://modernod.com/news/novartis-to-discontinue-development-of-ga-gene-therapy/2481824/Following weak phase 2 clinical data, Novartis decided to discontinue the clinical development of its geographic atrophy gene therapy candidate GT005, which it acquired as part of its acquisition of Gyroscope Therapeutics. The announcement was made by investment film Syncona, which prev
- Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Noregen for Retinal Diseaseshttps://modernod.com/news/caeregen-therapeutics-receives-14-million-phase-2-sbir-grant-from-nihnei-to-advance-development-of-regenerative-medicine-clinical-candidate-ctr-107-noregen-for-retinal-diseases/2481729/Caeregen Therapeutics announced that it has been awarded a $1.4 million phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen), a regenerative therapeutic for the treatme
- FDA Clears CorNeat EverPatch, World's First Non-Degradable, Synthetic Tissue Substitute for Ophthalmic Surgeryhttps://modernod.com/news/fda-clears-corneat-everpatch-worlds-first-non-degradable-synthetic-tissue-substitute-for-ophthalmic-surgery/2481668/The FDA has granted 510(k) clearance to CorNeat Vision's EverPatch, which the company describes as the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue an
- Nova Eye Medical Announces US Market Clearance of the iTrack Advance Canaloplasty Devicehttps://modernod.com/news/nova-eye-medical-announces-us-market-clearance-of-the-itrack-advance-canaloplasty-device/2481530/Nova Eye Medical announced that it has been granted FDA 510(k) clearance for its new canaloplasty device, iTrack Advance. The iTrack Advance has been cleared for microcatheterization and viscodilation to reduce IOP in adult patients with prim